Trial Profile
A Pilot Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 22 Aug 2022 Planned End Date changed from 1 Jan 2023 to 1 Jan 2026.
- 22 Aug 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.
- 22 Aug 2022 Status changed from recruiting to active, no longer recruiting.